Asset Manager

Updated:

Allurion Technologies

Allurion Technologies develops the Elipse gastric balloon for weight loss, operating in over 40 countries with a virtual care platform.

Allurion Technologies

Allurion Technologies was co-founded by Shantanu Gaur, a physician, and Samuel Levy, an engineer, in 2009. The company developed the Elipse Balloon, the only swallowable, fluid-filled gastric balloon for weight loss that is expelled naturally without endoscopy. Wealth origin is not publicly disclosed for the founders or the firm's principals. Allurion's strategy centers on product sales of its Elipse device, supplemented by a subscription-based digital coaching app that provides behavioral and nutritional support. Revenue is reported quarterly in SEC filings. The company went public via a SPAC merger with Compute Health Acquisition Corp. in August 2022, raising approximately $46.7M in gross proceeds. As of 2024, Allurion reported cumulative placements in over 100,000 patients across more than 40 countries. The company maintains its headquarters in Natick, Massachusetts, with a research facility in the region. In 2023, Allurion launched a direct-to-consumer program in the United States via its website. A structural differentiator is Allurion's combination of a medical device with a digital health platform, creating a vertically integrated weight-loss solution that bypasses traditional clinic-based models. This model reduces procedural costs and expands access to patients who lack insurance coverage for conventional bariatric procedures.

General information

Firm type

Asset Manager

Year founded

2009

AUM

Undisclosed

Location

Region

North America

Country

United States

City

Natick

Corporate office

Natick, MA, United States

Principals

Shantanu Gaur

CEO and Co-Founder

Samuel Levy

Co-Founder

Sector focus

MedTechDigital HealthHealthcare Services

Frequently asked questions

Who runs investment decisions at Allurion Technologies?

Allurion is a publicly traded medical device company, not a family office. Investment decisions are made by the board of directors and executive team, led by CEO Shantanu Gaur. No family office arm or affiliated investment entity is publicly known.

How does Allurion generate revenue?

Allurion generates revenue primarily through sales of its Elipse gastric balloon system to clinics and hospitals, along with a subscription-based digital weight-loss coaching app called the Allurion Program. Revenue is recognized upon device delivery and app subscriptions, per the firm's SEC filings.

Is Allurion structured as a family office or a medical device company?

Allurion is a publicly traded medical device company, listed on the NYSE under ticker ALUR. It does not operate as a family office. Its investor base includes institutional asset managers and venture capital firms, not a single-family office.

What investment stages does Allurion target?

Allurion does not make investments; it is a commercial-stage company that develops and markets medical devices. It has raised venture and public capital for its operations.

Which sectors does Allurion explicitly avoid?

Allurion focuses exclusively on MedTech and digital health for weight management. It has no publicly stated avoidance of any sector outside its core business.

How is Allurion related to Compute Health Acquisition Corp?

Allurion merged with Compute Health Acquisition Corp., a special purpose acquisition company (SPAC), in August 2022. The deal provided Allurion with public listing and capital. Compute Health was sponsored by existing Allurion investors.

Where does the underlying wealth come from for Allurion's founders?

The wealth of founders Shantanu Gaur and Samuel Levy is not publicly disclosed. Neither has publicly detailed personal financial origins. Gaur is a physician; Levy is an engineer with prior med-tech experience.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on family offices?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo